Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

Conditions

• Crohn's Disease

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• adalimumab — DRUG

Study Details

The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to evaluate safety

Key Dates

Start date

Jun 30, 2006

Status verified

Nov 2007

Completion

May 31, 2007

Study Design

Enrollment

1,000 participants

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Primary Outcome Measure

AEs, laboratory data, physical examinations and vital signs

Locations (97)

Find similar trials in Birmingham, AL

Related Studies

• Autologous Stem Cell Transplantation for Crohn's Disease
  PHASE1/PHASE2 · Recruiting · Paul Szabolcs · Pittsburgh, Pennsylvania
• Fecal Microbiome Transplant
  PHASE1 · Enrolling By Invitation · Judith Kelsen · Philadelphia, Pennsylvania
• Improving the Quality of Care for Adults With Inflammatory Bowel Disease
  Enrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
• An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
  PHASE1/PHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland